

The Xience V Stent Pipeline


Optimal Balance of Stent Performance and Safety

Chuck Simonton MD, FACC, FSCAI
Chief Medical Officer
Abbott Vascular
Santa Clara, CA
USA

DES Summit
TCT-AP
Seoul, Korea 2013

Disclosures


Chief Medical Officer
Divisional Vice President
Abbott Vascular
Santa Clara, CA, USA



XIENCE V[®] Components: Importance of Design

MULTI-LINK VISION Stent Design

Stent Delivery System



Everolimus

Biocompatible + Thromboresistant Fluoro-Copolymer Coating Technology

Indications: The XIENCE Family of Everolimus Eluting Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to *de novo* native coronary artery lesions (XIENCE V and XIENCE nano length \leq 28 mm and XIENCE PRIME and XIENCE PRIME LL length \leq 32 mm) with reference vessel diameters of 2.25 mm to 4.25mm

Scaffolding Overview & Design Characteristics


Stent Scaffolding:

- Provides sound structural support
- Prevent prolapse and secures dissections
- Promote optimal apposition to vessel wall

Links per Ring:


Fewer

- More Flexible
- Less Scaffolding



More


- Less Flexible
- More Scaffolding



Scaffolding: Optimal with Xience / Prime



Xience™ platform

- Peak to valley
- Long links
- 3 links per ring





Element™ platform

- Off-set peak to peak
- Short connectors
- 2 per ring



Integrity™ platform

- Peak to peak
- Welds
- Every 4th crest




Longitudinal Stability: Compression

Xience™ platform

Peak-to-Valley


3 Long Links



Integrity™ platform

Peak-to-peak

2 & 3 Welds



Element™ platform

Offset Peak-to-peak

2 Short Connectors



**Most Vulnerable to
Compression**

Longitudinal stent deformation: insights on mechanisms, treatments and outcomes from the Food and Drug Administration Manufacturer and User Facility Device Experience database

Mamas A. Mamas^{1,2*}, MA, DPhil, BM, BCh; Paul D. Williams¹, MA, BM, BCh, MD

1. Manchester Heart Centre, Manchester Royal Infirmary, Manchester, United Kingdom; 2. Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom

Mamas et al, Eurointervention March 2012

Rise in Longitudinal Case Complication Reports




Figure 2. Number of cases of longitudinal stent deformation submitted to MAUDE website according to year.

Table 1. Number of longitudinal stent deformation cases found on the MAUDE database according to stent platform.

Stent platform	Stent type	Number of cases (%)
Element (Boston Scientific)	Promus Element	34 (59.6%)
	Ion/TAXUS Element	8 (14.0%)
	Omega	3 (5.3%)
	Total	45 (78.9%)
Driver (Medtronic)	Endeavor	3 (5.3%)
	Driver	1 (1.8%)
	MicroDriver	1 (1.8%)
	Total	5 (8.9%)
CYPHER (Cordis)	CYPHER	3 (5.3%)
Nobori (Terumo)	Nobori	1 (1.8%)
Liberté (Boston Scientific)	TAXUS Liberté	1 (1.8%)
Multi-link Vision (Abbott Vascular)	XIENCE V	1 (1.8%)
Unidentified		1 (1.8%)

Mamas et al, Eurointervention March 2012

Xience Stent Design Summary

Multi-Link Geometry Advantages

Excellent Deliverability

Without Sacrificing:

Scaffolding


Longitudinal Strength

XIENCE® : Largest Body of Data: Over 40,000 Pts

Follow-Up: Trial	1-Year Purpose	2-Year	3-Year	4-Year	5-Year
Abbott-Sponsored Trials					
SPIRIT FIRST n = 60	Safety & Performance				
SPIRIT II n = 300	Clinical Support for CE Launch				ACC-11
SPIRIT III n = 1,002	U.S. & Japan Approval				TCT-11
SPIRIT IV n = 3,690	U.S. Peri-Approval		TCT-11		
SPIRIT V n = 2,663	Post CE-Mark Continued Follow-up				
XIENCE V USA n = 5,054 + 3000	Real World Registry		TCT-11		
SPIRIT WOMAN n = 1,572	Real World Single Arm Study		TCT-11		
SPIRIT PRIME Registry	TCT-11				


■ New 2011 Data

SPIRIT III: Target Lesion Failure at 5 Yrs



SPIRIT IV

Stent Thrombosis (ARC Def or Prob)



Number at risk

XIENCE V®	2458	2427	2413	2387	2358	2331	2319	2311	2296	2272	2263	2254	2242
TAXUS®	1229	1196	1186	1175	1157	1137	1131	1127	1115	1106	1098	1086	1073

Large Body of XIENCE DAPT Data

More than 13,000 Patients Out to 2 Years



ACC 2012
**SPIRIT-
COMPARE**

Dr. Elvin Kedhi

PCR 2010
**XIENCE V USA:
DAPT Analysis**
Dr. James Hermiller

PCR 2012
**3 Months DAPT
Analysis**
Dr. Tullio Palmerini

TCT 2011
**ST & DAPT
Mega-Meta
Analysis**
Dr. Gregg Stone

XIENCE V USA: Large U.S. Registry with a Highly Complex, Real-World Patient Population

XIENCE V USA


- Single-arm registry of **5,054 real-world patients**
- Primary endpoint of ARC Def/Prob stent thrombosis at 1 year

Patient and Lesion Distribution:

- | | |
|------------------------------|----------------------------|
| ✓ Left Main: 1.6% | ✓ CTO Lesions: 2.5% |
| ✓ AMI: 18.1% | ✓ EF <30%: 3.4% |
| ✓ ACS: 37.5% | ✓ Graft Lesions: 4.8% |
| ✓ Diabetes: 35.6% | ✓ Restenotic Lesions: 9.5% |
| ✓ Multivessel Disease: 40.8% | ✓ Ostial Lesions: 11.9% |
| ✓ Multivessel Treated: 13.8% | ✓ Bifurcations: 9.0% |
| ✓ Renal Insufficiency: 11.1% | ✓ Direct Stenting: 38.7% |

Source: Derived from J Hermiller, XIENCE V USA 1-Year Results, PCR 2010.

XIENCE V USA: 0% Stent Thrombosis with DAPT Interruption After 6 Months



Data Published in JACC Dec 2011

*Standard Risk patients in XIENCE V USA are those patients treated per labeling for XIENCE V in the U.S.

⁺ Out to 1-year. Source: Derived from Hermiller, J. PCR 2010.

DES Pipeline from Abbott Vascular

Continuing to Innovate

The Next Generations of DES

	XIENCE PRIME®	†XIENCE® Side-Branch Access	†Thinman DES	†4th Revolution ABSORB™
	XIENCE XPEDITION® CE 2012 US 2013			
E.U. 2006 U.S. 2008	E.U. 2009 U.S. 2011	C.E. Mark 2011	2014+	CE 2011 U.S. 2015

†Pipeline products currently in development. Not available for sale.

XIENCE Xpedition: Most Agile Xience

Designed to DELIVER








•The most agile XIENCE. Ever.

Coming Soon!
Pending CE Mark

Pipeline product currently in development at Abbott Vascular. Not available for sale.

XIENCE Xpedition

Designed for improved acute performance



	 Delivery System	 Balloon	 Stent Design and Material	 Drug/Dose	 Polymer
XIENCE PRIME	XIENCE PRIME Delivery System	Single-Layer Balloon	MULTI-LINK 8 Cobalt Chromium	Everolimus 88 µg	Biocompatible Coating Technology
XIENCE Xpedition	NEW! Smooth Transitions Delivery System	NEW! Multi-Layer Balloon for flatter compliance	↓	↓	↓

Pipeline product currently in development at Abbott Vascular. Not available for sale.

Coming Soon! Pending CE Mark


XIENCE Xpedition

Designed to be **TRACKABLE**



Integrated Tip

- Smooth tracking around sharp bends in tortuous anatomy



Slim Seal Technology



- Flexible, ultra low distal seal profile for outstanding crossability

Coming Soon!
Pending CE Mark

Pipeline product currently in development at Abbott Vascular. Not available for sale.

XIENCE Xpedition

Designed to be **FLEXIBLE**



More Flexible Balloon with Flatter Compliance

- Thin, multi-layered balloon walls for superb deliverability
- Taper optimized for balloon refold


Coming Soon!
Pending CE Mark

Pipeline product currently in development at Abbott Vascular. Not available for sale.

Xience Xpedition


Flatter Balloon Compliance

Flatter compliance enables higher pressure deployment for improved stent expansion in complex anatomy



XIENCE Xpedition

Designed to be **PUSHABLE**



Fewer and smoother transitions across entire system for more efficient force transfer

- Cross challenging anatomy with less force
- Excellent tactile feedback
- Strong and flexible distal shaft

Skive Transition for Improved Support

- Smooth transition between hypotube and distal shaft
- Reduced guide wire notch profile


Coming Soon!
Pending CE Mark

Pipeline product currently in development at Abbott Vascular. Not available for sale.

Xience Xpedition

Less Work to Track Through Tortuosity

Catheter Performance Test



ABSORB

The Fully Bioresorbable Vascular Scaffold

The Fourth Revolution of PCI!

